Sage Journals: Discover world-class research

Abstract

Two separate international standards, ISO 20072:2009 and ISO 27427:2010, have recently been published that relate to the development and performance testing of oral inhaled products (OIPs). The scope of ISO 20072 encompasses all OIP forms except nebulizing systems, whereas ISO 27427 was developed specifically for this class of OIP. Compliance with these standards will likely be necessary for manufacturers seeking approval to market inhaler devices in the European Union (EU). Their adoption in the United States may take a considerable time, but the FDA has expressed support in general terms for the ISO process. Key aspects of both standards that are very different in style and content are identified and discussed from the perspective of a potential user. In the approach adopted by ISO 20072, a formalized risk assessment is undertaken as a key part of design verification, in order to develop the Device Functionality Profile (DFP) of the device. The DFP is subsequently verified by the System Verification Test (SVT), in which pharmacopeial test methods are used to evaluate in vitro performance of the device with a chosen drug product in a statistically robust manner. On the other hand, ISO 27427 adopts a more prescriptive approach that involves performance verification of the finished nebulizing system using 1% w/v salbutamol as the test formulation. Although ISO 27427 is currently undergoing revision, at present it is unclear whether the changes that are made will significantly alter its fundamentally different approach to device performance verification. A strong case can be made for a single OIP-wide ISO standard, based on the principles developed in ISO 20072 and that makes use of the well-understood and validated in vitro test procedures that are available or will shortly be available in the case of nebulizing systems, in the United States and European pharmacopeias.

Get full access to this article

View all access options for this article.

References

European Parliament and Council: Directive 2007/47/EC of September 5, 2007. Off J Eur UnionL247/212007.

Premarket approval of medical devices: United States Code of Federal Regulations2011, Title 21; 8: Part. 814http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?type=simple;c=ecfr;cc=ecfr;idno=21;region=DIV1;q1=814;rgn=div5;sid=a96044f58ab9c1b85326a0cf05cf05c0;view=text;node=21%3A8.0.1.1.11. 2011 September 21.

Medical Device Regulations: Global Overview and Guiding Principles. World Health Organization: Geneva, Switzerland, 2003. http://www.who.int/medical_devices/publications/en/MD_Regulations.pdf. 2011 September 21.

ISO13485:2003: Medical Devices—Quality Management Systems—Requirements for Regulatory Purposes. International Standards Organization: Geneva, Switzerland.

ISO 9001:2008: Quality Management. International Standards Organization: Geneva, Switzerland.

United States Federal Drug Administration (USFDA): Reviewer Guidance for Nebulizers Metered Dose Inhalers Spacers, Actuators. Office of Device Evaluation: Rockville, MD, USA, October 1993. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm081282.htm. 2011 September 21.

U.S. Department of Health and Human Services, Food and Drug Administration: Draft guidance for industry, third parties, and FDA staff: Medical Device ISO 13485:2003 Voluntary Audit Report Submission Program. CDRH/CBER: Rockville, MD, USA, May 2010. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM212798.pdf September 21, 2011.

Newman

. Principles of metered-dose inhaler design. Respir Care, 2005; 50:1177–1190.

U.S. Department of Health and Human Services, Food and Drug Administration: Integration of Dose-Counting Mechanisms into MDI Drug Products. U.S. Department of Health and Human Services, Food and Drug Administration: Rockville, MD, USA, March 2003. http://www.fda.gov/cder/guidance/5308FNL.htm. 2011 September 21.

10.

Mitchell

, Dalby

. Characterization of aerosol performance. Bechtold-Peters

, Lüssen

. Pulmonary Drug Delivery—Basics, Applications and Opportunities for Small Molecules and Bio-PharmaceuticalsChapter 14Editio Cantor Verlag: Aulendorf, Germany, 282–305. 2006.

11.

British Standard 7711-3 (now withdrawn): Respiratory Therapy Equipment. Specification for Gas-Powered Nebulizers for the Delivery of Drugs. British Standards Institute: UK, 1994.

12.

European Committee for Standardization (CEN): EN 13544-1(now superseded). Respiratory Therapy Equipment—Part 1: Nebulizing Systems and Their Components. CEN: Brussels, Belgium, 2001.

13.

Boe

, Dennis

, O'Driscoll

, Bauer

, Carone

, Dautzenberg

, Diot

, Heslop

, Lannefors

. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J, 2001; 18:228–242.

14.

ISO 20072:2009: Aerosol Drug Delivery Device Design Verification—. Requirements Test Methods. International Standards Organization: Geneva, Switzerland.

15.

ISO 27427:2010: Anaesthetic. Respiratory Equipment—Nebulizing Systems Components. International Standards Organization: Geneva, Switzerland.

16.

ISO 14971:2007: Medical Devices—Application of Risk Management to Medical Devices. International Standards Organization: Geneva, Switzerland.

17.

U.S. Department of Health and Human Services, Food and Drug Administration: Quality Systems Approach to Pharmaceutical CGMP Regulations. U.S. Department of Health and Human Services. Food and Drug Administration: Rockville, MD, September 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070337.pdf. 2011 September 21.

18.

United States Pharmacopeial Convention (USP): Chapter 601: Aerosols, Metered-Dose Inhalers Dry Powder Inhalers. USP33-NF28. 2007.

19.

European Directorate for Quality of Medicines in Healthcare (EDQM): Preparations for Inhalations: Aerodynamic Assessment of Fine Particles. Monograph 2.9.18 of the European Pharmacopeia. Strasbourg: Council of Europe, 2010.

20.

United States Pharmacopeial Convention:. In process revision. Chapter 1601. Products for nebulization—characterization tests. Pharm Forum, 2010; 36:534–539.

21.

European Directorate for Quality in Medicines and Healthcare (EDQM). Preparations for Nebulisation: Characterisation. Monograph 2.9.44. of the European Pharmacopeia. Strasbourg: Council of Europe, 2012.

22.

Mitchell

J.P.

, Nagel

M.W

. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med, 2003; 16:341–377.

23.

Dhand

. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care, 2007; 57:866–884.

24.

Phipps

, Gonda

. Droplets produced by medical nebulizers: some factors affecting their size and solute concentration. Chest, 1990; 97:1327–1332.

25.

Stapleton

, Finlay

. Determining solute concentration within aerosol droplets output by jet nebulizers. J Aerosol Sci, 1995; 26:137–145.

26.

Niven

. Atomization, nebulizers. Hickey

. Inhalation Aerosols: Physical and Biological Basis for Therapy. Marcel Dekker: New York, 273–312. 1996.

27.

Hess

D.R.

Nebulizers: principles and performance. Respir Care, 2000; 45:609–622.

28.

International Standards Organization: ISO/CD 27427. Anaesthetic and Respiratory Equipment—Nebulizing Systems and Components. International Standards Organization. Geneva, Switzerland http://www.iso.org/iso/iso_catalogue/catalogue_ics/catalogue_detail_ics.htm?csnumber=59482. 2011 September 21.

Comparison of ISO Standards for Device Performance;20072 and 27427: A Critical Appraisal

Abstract

Abstract

Get full access to this article

References